{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:55:09Z","timestamp":1789181709926,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10006-020-00913-z","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T11:02:41Z","timestamp":1602327761000},"page":"149-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Osteonecrosis of the jaws associated with protein kinase inhibitors: a systematic review"],"prefix":"10.1007","volume":"25","author":[{"given":"Mustafa","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashaan","family":"Sreedharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"issue":"2","key":"913_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","volume":"61","author":"S Kuroshima","year":"2019","unstructured":"Kuroshima S, Sasaki M, Sawase T (2019) Medication-related osteonecrosis of the jaw: a literature review. J Oral Biosci 61(2):99\u2013104","journal-title":"J Oral Biosci"},{"issue":"4","key":"913_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","volume":"127","author":"R King","year":"2019","unstructured":"King R, Tanna N, Patel V (2019) Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol 127(4):289\u2013299","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"10","key":"913_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72(10):1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"913_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00018-008-8539-7","volume":"66","author":"SK Grant","year":"2009","unstructured":"Grant SK (2009) Therapeutic protein kinase inhibitors. Cell Mol Life Sci 66(7):1163\u20131177","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"913_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bjoms.2019.11.022","volume":"58","author":"P Shah","year":"2020","unstructured":"Shah P, Dylgjeri F, Srinivasan B, Brennan PA (2020) Oral tyrosine kinase inhibitors in OMFS: a review. Brit J Oral Max Surg 58(2):135\u2013138","journal-title":"Brit J Oral Max Surg"},{"key":"913_CR6","doi-asserted-by":"crossref","unstructured":"Patterson H et al (2013) Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol 176","DOI":"10.1111\/cei.12248"},{"issue":"1","key":"913_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular cancer 17(1):48\u201348","journal-title":"Molecular cancer"},{"issue":"3","key":"913_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26(3):869\u2013878","journal-title":"Support Care Cancer"},{"issue":"6","key":"913_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1084\/jem.20132330","volume":"211","author":"C Raimondi","year":"2014","unstructured":"Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh A, Ruhrberg C (2014) Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J Exp Med 211(6):1167\u20131183","journal-title":"J Exp Med"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-2-45","volume":"2","author":"R Yuan","year":"2009","unstructured":"Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45\u201345","journal-title":"J Hematol Oncol"},{"issue":"3","key":"913_CR11","doi-asserted-by":"publisher","first-page":"R247","DOI":"10.1530\/ERC-12-0400","volume":"21","author":"JO Aleman","year":"2014","unstructured":"Aleman JO, Farooki A, Girotra M (2014) Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer 21(3):R247\u2013R259","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"913_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336\u2013341","journal-title":"Int J Surg"},{"key":"913_CR13","unstructured":"American Society of Plastic Surgeons (ASPS). ASPS evidence rating scales 2011."},{"issue":"2","key":"913_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine 23(2):60\u201363","journal-title":"BMJ Evidence-Based Medicine"},{"key":"913_CR15","doi-asserted-by":"crossref","unstructured":"Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M (2018) Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125(2):157\u2013163.","DOI":"10.1016\/j.oooo.2017.10.010"},{"issue":"7","key":"913_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bjoms.2019.05.017","volume":"57","author":"S Akkach","year":"2019","unstructured":"Akkach S, Shukla L, Morgan D (2019) Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. Br J Oral Maxillofac Surg 57(7):688\u2013690","journal-title":"Br J Oral Maxillofac Surg"},{"key":"913_CR17","doi-asserted-by":"crossref","unstructured":"Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F\u00a0(2016) Regorafenib Also Can Cause Osteonecrosis of the Jaw. J Natl Cancer Inst 108(4)","DOI":"10.1093\/jnci\/djw002"},{"issue":"3","key":"913_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","volume":"113","author":"Y Fleissig","year":"2012","unstructured":"Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 113(3):e1-3","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"913_CR19","doi-asserted-by":"crossref","unstructured":"Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F (2016) Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori J 102","DOI":"10.5301\/tj.5000504"},{"issue":"2","key":"913_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","volume":"3","author":"T-Y Jung","year":"2017","unstructured":"Jung T-Y (2017) Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient. Oral and Maxillofacial Surgery Cases 3(2):27\u201333","journal-title":"Oral and Maxillofacial Surgery Cases"},{"issue":"1","key":"913_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","volume":"15","author":"FP Koch","year":"2011","unstructured":"Koch FP, Walter C, Hansen T, Jager E, Wagner W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15(1):63\u20136","journal-title":"Oral Maxillofac Surg"},{"key":"913_CR22","doi-asserted-by":"crossref","unstructured":"Lee C, Lee K, Md K, Mba J (2016) Medication-Related Osteonecrosis of the Jaw with the mTOR Inhibitor Everolimus in a Patient with Estrogen-Receptor Positive Breast Cancer: A Case Report. Int J Dent Hyg 2","DOI":"10.23937\/2469-5734\/1510033"},{"issue":"4","key":"913_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/adj.12254","volume":"60","author":"R Marino","year":"2015","unstructured":"Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M (2015) Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J 60(4):528\u201331","journal-title":"Aust Dent J"},{"issue":"12","key":"913_CR24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","volume":"48","author":"R Mauceri","year":"2019","unstructured":"Mauceri R, Panzarella V, Morreale I, Campisi G (2019) Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 48(12):1530\u20131532","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"2","key":"913_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00238-015-1112-3","volume":"39","author":"C Melloni","year":"2016","unstructured":"Melloni C, Tuttolomondo A, Anfosso A, Calamia C, Clemente FD, Cordova A (2016) Sunitinib related osteonecrosis of the jaw (SURONJ): a rare occurrence? Eur J Plast Surg 39(2):161\u2013162","journal-title":"Eur J Plast Surg"},{"issue":"2","key":"913_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","volume":"113","author":"O Nicolatou-Galitis","year":"2012","unstructured":"Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T et al (2012) Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 113(2):234\u20138","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"913_CR27","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","volume":"124","author":"V Patel","year":"2017","unstructured":"Patel V, Sproat C, Kwok J, Tanna N (2017) Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 124(5):e257\u2013e260","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"913_CR28","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","volume":"124","author":"V Patel","year":"2017","unstructured":"Patel V, Sproat C, Kwok J, Tanna N (2017) Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 124(5):e257\u2013e260","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"913_CR29","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/j.oooo.2018.05.008","volume":"126","author":"AM Won","year":"2018","unstructured":"Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M (2018) Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 126(4):e208\u2013e211","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"913_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3892\/mco.2016.1100","volume":"6","author":"D Yamamoto","year":"2017","unstructured":"Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K et al (2017) Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol 6(2):255\u2013257","journal-title":"Mol Clin Oncol"},{"key":"913_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23808993.2016.1140555","volume":"1","author":"M Bianconi","year":"2016","unstructured":"Bianconi M et al (2016) Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand? Expert Rev Precis Med Drug Dev 1:1\u20133","journal-title":"Expert Rev Precis Med Drug Dev"},{"issue":"11-12Suppl7","key":"913_CR32","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.5489\/cuaj.4307","volume":"10","author":"A Kapoor","year":"2016","unstructured":"Kapoor A (2016) First-line treatment options in metastatic renal cell cancer. Can Urol Assoc J 10(11-12Suppl7):S236\u2013S238","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"913_CR33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","volume":"26","author":"M Schiodt","year":"2018","unstructured":"Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, Fedele S, Jandial D, Zhang J, Ma H, Saunders DP (2018) A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26(6):1905\u20131915","journal-title":"Support Care Cancer"},{"issue":"4","key":"913_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 24(4):527\u2013536","journal-title":"Oral Dis"},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","volume":"144","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr (2019) Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 144:19\u201350","journal-title":"Pharmacol Res"},{"key":"913_CR36","doi-asserted-by":"publisher","first-page":"8768162","DOI":"10.1155\/2016\/8768162","volume":"2016","author":"T Lombard","year":"2016","unstructured":"Lombard T et al (2016) Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int 2016:8768162\u20138768162","journal-title":"Stem Cells Int"},{"key":"913_CR37","doi-asserted-by":"publisher","first-page":"1801676","DOI":"10.1155\/2016\/1801676","volume":"2016","author":"G Favia","year":"2016","unstructured":"Favia G et al (2016) Medication-related osteonecrosis of the jaws: considerations on a new antiresorptive therapy (denosumab) and treatment outcome after a 13-year experience. Int Dent J 2016:1801676\u20131801676","journal-title":"Int Dent J"},{"issue":"4","key":"913_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/odi.12632","volume":"23","author":"P Fung","year":"2017","unstructured":"Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schi\u00f8dt M, Lakatos P, Taylor T, de Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P, GENVABO Consortium, Fedele S (2017) Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis 23(4):477\u2013483","journal-title":"Oral Dis"},{"issue":"5","key":"913_CR39","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23(5):1341\u20131347","journal-title":"Ann Oncol"},{"key":"913_CR40","unstructured":"U.S. Food, Drug Administration. FDA online label repository (2020) [cited 2020 5\/4\/2020]; Available from: https:\/\/labels.fda.gov\/."},{"issue":"29","key":"913_CR41","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EEW, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639\u20133646","journal-title":"J Clin Oncol"},{"key":"913_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2017.07.031","volume":"85","author":"A Ravaud","year":"2017","unstructured":"Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon\u2013P\u00e9richout D, Doussau A, Molimard M, Delord JP (2017) Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: results of EVAX study. Eur J Cancer 85:39\u201348","journal-title":"Eur J Cancer"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-020-00913-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-020-00913-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-020-00913-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:16:52Z","timestamp":1633915012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-020-00913-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1007\/s10006-020-00913-z","relation":{},"ISSN":["1865-1550","1865-1569"],"issn-type":[{"value":"1865-1550","type":"print"},{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"8 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}